You're correct about me adding. PPS down because of market sickness in general, plus no news expected until Q4.
Does not make sense to me that PT is 21, pps was at 17, yet it is hold instead of buy.
What date was the VHC 10K? I can't find it.
I only found this:
In addition, if the Company (Leidos) receives any proceeds under its agreements with VirnetX, the Company is required to pay a royalty on the proceeds received to the customer who paid for the development of the technology.
I am long, that's why I cheer
You play short and so you jeer.
I just go where the money flows.
That's just how this game goes.
You're a bear. I'm a bull.
Take it easy. Play it cool.
Man...I am good!
You gotta at least agree with that!
Definitely a concern as a competitor. It may affect Erivedge sales in 6 mos. However, it's hard to tell without a side by side comparison as to whether one works better than the other. Because doctors are already comfortable with Erivedge, it may take a while before E sales may be affected. By then, Curis may have already been bought out.
So the funds shorted at say $20, covered at $18, and are now driving it back up to $20 and selling, for a quick gain of $4/share.
Of course, the brokers also know about the stock offering, so they shorted at $21 and they probably are getting their shares at less than $17. A quick $7/share profit for those robbers. Now drive the pps back up to 21 and that's up to $8/share.
So who's really losing out? Some small time investors. I would say 401k and pension investments. Since I have money in all 3, that means I am losing some money!
This institutionalize robbery should be stopped!
"Tumors shrank or disappeared completely for eight or more weeks in four study participants, including three adults, following vismodegib treatment. In 13 patients, or 41 percent of participants with SHH medulloblastoma, disease stabilized and tumors stopped growing for as long as 17 months during vismodegib therapy.
The findings led to the drug being included in the St. Jude clinical trial for newly diagnosed pediatric medulloblastoma patients aged 3 to 22 years old. Patients with SHH medulloblastoma receive vismodegib as maintenance therapy.
Just out in Medexpress:
"A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital.
The drug, called vismodegib, is designed to block a key protein in the sonic hedgehog (SHH) signaling pathway. The pathway is normally active during fetal development and is inappropriately switched on in about 30 percent of medulloblastoma tumors, including about 60 percent of tumors in adults and 25 percent of tumors in children."
ZGNX mgmt is not rare. Many small companies declare that they have enough funds for two more years of operation and don't need to raise more yada yada, then in less than 3 months hit longs with a stock offering. In ZGNX case, with the huge run up and pps inflation, I think it is actually a good decision by mgmt. Would have been bad if pps was at $13 and they decided to sell shares.
I actually think that Ariad will get better partnering terms once the first Briga trial has final results, assuming the results will turn out as good as expected. Of course, if the outstanding results continue, it may even be best if Ariad does it alone. Ariad is in a good position to keep ownership of Briga given the money from PDL.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success."
Following multiple unsuccessful courses of treatment, the patient was referred to the University of Colorado for enrollment in the Phase 1 trial of LOXO-101 in March 2015. On study, the patient's shortness of breath rapidly resolved and she was able to discontinue her supplemental oxygen and resume activities of daily living. Imaging studies following one month of treatment, the first imaging studies conducted post-treatment, confirmed that her tumors had substantially regressed, meeting a partial response (PR) definition by standard RECIST 1.1 criteria. As discussed in the publication, with 4 months of treatment, additional CT scans demonstrated almost complete tumor disappearance of the largest tumors. After 4 months of dosing, the patient did not have any adverse events that were attributed to LOXO-101.
Long term, those numbers will indicate when IMGN can expect to partake of the royalties again. In 6-7 yrs, some of the sales royalties will trickle into IMGN coffers again. Better if sooner. Perhaps with gastric indication, plus other HER+ cancers.
Is it possible that Roche makes more money from selling Herceptin and Perjeta, vs selling Kadcyla? One thing is that H + P combo is probably less toxic too compared to "Kadzilla", except for the taxane that is used with H&P. Anyway, seems like in 6 or 7 yrs, if Kadcyla sales continue to increase, IMGN should be able to partake of some of the sales royalties again. By that time, hopefully there's also one or 2 additional DM conjugates in the market.